- Advaxis (ADXS +9.2%) enters into a co-development and commercialization agreement with privately held Mexican specialty pharmaceutical firm Especificos Stendhal SA de CV for axalimogene filolisbac (formerly ADXS-HPV) in HPV-associated cancers.
- Under the terms of the deal, Stendahl will pay $10M toward the expenses of conducting a planned global Phase 3 study, AIM2CERV, assessing axalimogene filolisbac in women with high-risk, locally advanced cervical cancer. Advaxis will assist Stendahl to complete the study in Latin American markets while Stendahl will manage the regulatory approval process and commercialization activities.
- The companies will share profits on an undisclosed basis.
- Axalimogene filolisbac is an immunotherapy based on the company's Lm Technology, which uses live attenuated bioengineered Listeria bacteria to deliver a fusion protein inside cancer cells which then stimulates the immune system to attack the cancer.
Advaxis inks deal for commercialization of lead product candidate in Latin America
Recommended For You
About ADXS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ADXS | - | - |
Ayala Pharmaceuticals, Inc. |